Carl Zeiss Still Committed to the Fight against Tuberculosis
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Carl Zeiss is continuing its commitment to the fight against tuberculosis, a disease to which World TB Day on 24 March aims to draw the public’s attention every year.
Carl Zeiss is now providing the Primo Star iLED fluorescence microscope at an attractive price to 74 instead of 22 countries with a high incidence of tuberculosis. The countries that can benefit from this price are all countries that have a TB incidence of > 100 per 100 K population and, at the same time; are low- or low and middle-income economies.
Carl Zeiss is a member of the Stop TB Initiative, whose aim is to eliminate TB as a public health problem and, ultimately, to contribute to a world free of tuberculosis.
The sturdy and easy-to-use Primo Star iLED microscope, developed and launched on the market by Carl Zeiss together with FIND (Foundation for Innovative New Diagnostics) in 2008, allows up to 4 times faster detection of tuberculosis than with traditional techniques, the company claims.
“To help more efficiently, we think it is essential to increase the number of countries with a high load of TB that can benefit from our particularly favorable price for the Primo Star iLED. We live our corporate social responsibility and we are strongly committed to help with our innovative techno- logies,” said Dr. Thomas Bocher, Business Unit Manager at Carl Zeiss MicroImaging GmbH.
This is a very promising announcement. We can only applaud the decision to make this improved and robust microscope more affordable to those regions that most need such a tool to better screen and provide earlier treatment to TB patients,” says Dr. Giorgio Roscigno, Chief Executive Officer of FIND. “I am glad to see that through our strong partnership with Carl Zeiss, we are making significant progress to make better diagnostics accessible to all.”
Carl Zeiss is now providing the Primo Star iLED fluorescence microscope at an attractive price to 74 instead of 22 countries with a high incidence of tuberculosis. The countries that can benefit from this price are all countries that have a TB incidence of > 100 per 100 K population and, at the same time; are low- or low and middle-income economies.
Carl Zeiss is a member of the Stop TB Initiative, whose aim is to eliminate TB as a public health problem and, ultimately, to contribute to a world free of tuberculosis.
The sturdy and easy-to-use Primo Star iLED microscope, developed and launched on the market by Carl Zeiss together with FIND (Foundation for Innovative New Diagnostics) in 2008, allows up to 4 times faster detection of tuberculosis than with traditional techniques, the company claims.
“To help more efficiently, we think it is essential to increase the number of countries with a high load of TB that can benefit from our particularly favorable price for the Primo Star iLED. We live our corporate social responsibility and we are strongly committed to help with our innovative techno- logies,” said Dr. Thomas Bocher, Business Unit Manager at Carl Zeiss MicroImaging GmbH.
This is a very promising announcement. We can only applaud the decision to make this improved and robust microscope more affordable to those regions that most need such a tool to better screen and provide earlier treatment to TB patients,” says Dr. Giorgio Roscigno, Chief Executive Officer of FIND. “I am glad to see that through our strong partnership with Carl Zeiss, we are making significant progress to make better diagnostics accessible to all.”
